CPIM
ALXN

Columbia Partners Investment Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Columbia Partners Investment Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-41,709
Closed -$5.81M – 377
2016
Q1 		$5.81M Buy
41,709
+116
+0.3% +$17K 0.41% 90
2015
Q4 		$7.93M Buy
41,593
+182
+0.4% +$31.8K 0.55% 63
2015
Q3 		$6.48M Sell
41,411
-854
-2% -$156K 0.45% 85
2015
Q2 		$7.64M Sell
42,265
-7,623
-15% -$1.32M 0.47% 87
2015
Q1 		$8.64M Sell
49,888
-1,870
-4% -$338K 0.46% 83
2014
Q4 		$9.58M Sell
51,758
-1,091
-2% -$202K 0.5% 78
2014
Q3 		$8.76M Sell
52,849
-870
-2% -$143K 0.45% 85
2014
Q2 		$8.39M Sell
53,719
-705
-1% -$111K 0.39% 96
2014
Q1 		$8.28M Buy
54,424
+12,277
+29% +$1.95M 0.36% 106
2013
Q4 		$5.6M Sell
42,147
-401
-0.9% -$48.1K 0.24% 137
2013
Q3 		$4.94M Sell
42,548
-861
-2% -$94.5K 0.22% 146
2013
Q2 		$4M Buy
+43,409
New +$4.18M 0.19% 167

Other funds holding ALXN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Columbia Partners Investment Management's ALXN Position: Q2 2016 in Review

Columbia Partners Investment Management sold out of Alexion Pharmaceuticals (ALXN) in Q2 2016, closing a stake of 41,709 shares — an estimated $5.81M sold.

Columbia Partners Investment Management first reported a position in ALXN in Q2 2013 and held it in 12 quarters. The position peaked at $9.58M in Q4 2014. 534 funds tracked by Wall St. Rank hold ALXN as of Q2 2016.

  • Columbia Partners Investment Management reported no remaining Alexion Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Columbia Partners Investment Management sold 41,709 Alexion Pharmaceuticals shares in Q2 2016, an estimated $5.81M.
  • Columbia Partners Investment Management first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 12 quarters.
  • Columbia Partners Investment Management's Alexion Pharmaceuticals position peaked at $9.58M in Q4 2014.
  • 534 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2016.

Based on Columbia Partners Investment Management's 13F filing for Q2 2016, filed 10 Aug 2016.